Abstract
This section describes the risk stratification for pulmonary embolism (PE) and the current guidelines for advanced therapies for VTE. Various testing modalities are discussed in stratifying PE, and treatment options for each clinical severity are reviewed. The main treatment for all PE is anticoagulation; however, in cases of massive and submassive PE, additional remedies can include systemic thrombolysis, catheter-directed and percutaneous mechanical thrombectomy. Anticoagulation is also the main treatment for deep vein thrombosis, but catheter-directed therapy and stent placement can also be considered in very symptomatic patients with proximal thrombosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- aPTT:
-
Activated partial thromboplastin time
- CDT:
-
Catheter-directed thrombolysis
- CTPA:
-
Computed tomography pulmonary angiogram
- CTPH:
-
Chronic thromboembolic pulmonary hypertension
- DVT:
-
Deep vein thrombosis
- ESC:
-
European Society of Cardiology
- IFDVT:
-
Iliofemoral DVT
- LMWH:
-
Low molecular weight heparin
- NOAC:
-
Novel oral anticoagulants
- PE:
-
Pulmonary embolism
- PMT:
-
Percutaneous mechanical thrombectomy
- PTP:
-
Pre-test probability
- PTS:
-
Post thrombotic syndrome
- tPA:
-
Alteplase
- UFH:
-
Unfractionated heparin
- V/Q:
-
Ventilation perfusion scan
- VKA:
-
Vitamin K antagonists
- VTE:
-
Venous thromboembolism
References
Kearon C, Ageno W, Cannegieter SC, Cosmi B, Geersing G-J, Kyrle PA. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480–3.
Lim W, Le Gal G, Bates S, Righini M, Haramati L, Lang E, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: diagnosis of venous thromboembolism. Blood Adv. 2018;2(22):3226–56.
Perelas A, Dimou A, Saenz A, Rhee JH, Teerapuncharoen K, Rowden A, et al. Incidental findings on computed tomography angiography in patients evaluated for pulmonary embolism. Ann Am Thorac Soc. 2015;12(5):689–95.
Stein P, Fowler S, Goodman L, Gottschalk A, Hales C, Hull R, et al. Multidetector computed tomography for acute pulmonary embolism. N Engl J Med. 2006;354(22):2317–27.
Jaff M, McMurtry M, Archer S, Cushman M, Goldenberg N, Goldhaber S, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension. Circulation. 2011;123(16):1788–830.
Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(43):3033–80.
Vanni S, Jimenez D, Nazerian P, Morello F, Parisi M, Daghini E, et al. Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. Thorax. 2015;70(4):333–8.
Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky R, Sardar P, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage. JAMA. 2014;311(23):2414.
Corsi F, Lebreton G, Bréchot N, Hekimian G, Nieszkowska A, Trouillet J, et al. Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Critical Care. 2017;21(1):76.
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–11.
Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” trial). Am J Cardiol. 2013;111(2):273–7.
Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315–52.
Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, et al. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. Eur Heart J. 2019;41:509.
Mismetti P, Laporte S, Pellerin O, Ennezat P, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism. JAMA. 2015;313(16):1627.
Konstantinides S, Geibel A, Kasper W, Olschewski M, Blümel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation. 1998;97(19):1946–51.
Pengo V, Lensing A, Prins M, Marchiori A, Davidson B, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–64.
Douketis J, Crowther M, Foster G, Ginsberg J. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med. 2001;110(7):515–9.
Kahn S. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149(10):698.
Vedantham S, Goldhaber S, Julian J, Kahn S, Jaff M, Cohen D, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017;377(23):2240–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Wang, S., McDaniel, M. (2020). Pulmonary Embolism and DVT. In: Wells, B., Quintero, P., Southmayd, G. (eds) Handbook of Inpatient Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-47868-1_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-47868-1_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-47867-4
Online ISBN: 978-3-030-47868-1
eBook Packages: MedicineMedicine (R0)